Marea Therapeutics doses first patient in Phase 2 acromegaly trial of MAR002
LSTA•Marea Therapeutics, a Lisata Therapeutics subsidiary, dosed the first patient in a Phase 2 trial of MAR002 for acromegaly. The trial plans to enroll about 72 participants across three dose arms and placebo, with IGF-1 reduction after 10 weeks as its primary endpoint.
1. Trial begins
The Phase 2 trial will evaluate MAR002, an investigational allosteric monoclonal antibody targeting the growth hormone receptor to suppress IGF-1. It plans to enroll about 72 participants across three dose arms, using a 900 mg loading dose, and a placebo group. Eligible participants can enter an open-label extension.
2. Earlier trial data
Phase 1 data presented in June 2026 indicated deep, durable IGF-1 suppression, with dosing potentially as infrequently as every two weeks.
